Data from Phase II Trial on Investigational Oral Asthma Medication Show Promise by Targeting Airway Muscles
Posted On: February 28, 2019
In the latest issue of Science Translational Medicine, researchers from the U.K. demonstrated positive results in the treatment of asthma with a new oral medication
This investigational drug, fevipiprant, blocks the prostaglandin D2 receptor, which has been implicated in allergic asthma. In this study, researcher demonstrated with biopsies of the airway that use of the medication led to decreased inflammation (through reduced airway smooth muscle mass, decreased eosinophilia among other markers.)
More research needs to be done and likely the medication is years from getting F.D.A, approval. However, once approved, the medication may provide another tool for the allergist to help manage difficult-to-treat asthma.
For more information, please visit this link: stm.sciencemag.org/content/